Squamous cell carcinoma of the cervix – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:11 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Squamous cell carcinoma of the cervix – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of pembrolizumab and vorinostat combination therapy in patients with recurrent or metastatic squamous cell carcinoma of head and neck, cervix, anus, and genital areas https://clinicaltrials.eu/trial/study-on-pembrolizumab-and-vorinostat-for-patients-with-recurrent-or-metastatic-squamous-cell-carcinoma/ Wed, 29 Apr 2026 14:56:48 +0000 https://clinicaltrials.eu/trial/study-on-pembrolizumab-and-vorinostat-for-patients-with-recurrent-or-metastatic-squamous-cell-carcinoma/ This study focuses on several types of squamous cell carcinoma that have spread or returned after previous treatment, including cancers of the head and neck, cervix, anus, vulva/vagina, and penis. The study tests a combination of two medications: pembrolizumab, which is given through an intravenous injection, and vorinostat, which is taken as an oral capsule. The purpose is to evaluate how well these medications work together in treating these types of cancer.

The treatment involves receiving pembrolizumab as an infusion at a dose of up to 200 mg, along with vorinostat capsules at a dose of up to 400 mg daily. The treatment period may continue for up to 105 weeks. During the study, doctors will monitor how the cancer responds to the treatment combination through regular medical examinations and imaging tests.

Both medications work differently to fight cancer. Pembrolizumab is an immunotherapy drug that helps the body’s immune system recognize and attack cancer cells. Vorinostat belongs to a group of medications that work by affecting how genes behave in cancer cells. This combination approach aims to provide better results than using either medication alone.

]]> Study on the Safety and Effects of Durvalumab and Tremelimumab with Radiotherapy for Patients with Metastatic Squamous Cell Carcinoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-durvalumab-and-tremelimumab-with-radiotherapy-for-patients-with-metastatic-squamous-cell-carcinoma/ Wed, 29 Apr 2026 14:27:31 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-durvalumab-and-tremelimumab-with-radiotherapy-for-patients-with-metastatic-squamous-cell-carcinoma/ This clinical trial is focused on studying a type of cancer called metastatic squamous cell carcinoma, which can occur in areas such as the head and neck, lungs, esophagus, cervix, vagina, vulva, or anus. The study is testing a combination of treatments to see how safe and effective they are. The treatments being tested include two medications: Durvalumab (also known by its code name MEDI4736) and Tremelimumab. These medications are given together with a type of radiation therapy called stereotactic body radiotherapy (SBRT), which is a precise form of radiation treatment.

The purpose of the study is to evaluate the safety and clinical activity of these treatments when used together. Participants in the study will receive the medications and radiation therapy, and their health will be monitored to see how their cancer responds to the treatment. The study will also look at any side effects that may occur. The trial is divided into two phases: the first phase focuses on safety, while the second phase looks at how well the treatment works in reducing cancer outside the area that receives radiation.

Throughout the study, participants will undergo various medical assessments, including imaging tests like CT scans, to track the progress of their cancer and any changes in their condition. The study aims to provide valuable information on the potential benefits and risks of using Durvalumab and Tremelimumab in combination with SBRT for treating this type of cancer.

]]>